摘要
减少淀粉样-β(Aβ)的积累是治疗阿尔茨海默病(AD)疗法的一种很有发展前景的方法。我们最近报道了一种三苯甲烷食物染料模拟物,亮蓝G(BBG),是细胞实验中体外淀粉样-β聚集和细胞毒性的剂量依赖性调制器。在这最近的工作中,我们试图进一步在治疗相关的AD转基因小鼠模型中评价这种新型调制器。使APPSwDI/NOS2-/- 小鼠口服BBG三个月以评估其生物相容性,其穿过血脑屏障的渗透性和其在治疗AD症状时的疗效。结果表明,BBG的耐受性良好,没有造成显着的体重变化/不寻常的行为,并能够显著的跨ADAPPSwDI/NOS2-/- 小鼠血脑屏障。免疫组织化学和电子脑切片的显微分析表明,BBG能够显著抑制神经元的损失和减少海马神经元细胞内的APP /β。这是第一个报告1)亮蓝G在AD转基因动物模型对神经元损失的影响,2)口服BBG影响蛋白质构象/聚集病,和3)电镜超微结构分析APPSwDI/NOS2-/- 小鼠的AD病理。
关键词: 阿尔茨海默病,淀粉样-β,血脑屏障,细胞内淀粉样-β,神经元损失,三苯甲烷染料
Current Alzheimer Research
Title:Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model
Volume: 13 Issue: 6
Author(s): Jacob A. Irwin, Alev Erisir, Inchan Kwon
Affiliation:
关键词: 阿尔茨海默病,淀粉样-β,血脑屏障,细胞内淀粉样-β,神经元损失,三苯甲烷染料
摘要: Reducing amyloid-β (Aβ) accumulation is a promising strategy for developing Alzheimer’s Disease (AD) therapeutics. We recently reported that a triphenylmethane food dye analog, Brilliant Blue G (BBG), is a dose-dependent modulator of in vitro amyloid-β aggregation and cytotoxicity in cell-based assays. Following up on this recent work, we sought to further evaluate this novel modulator in a therapeutically-relevant AD transgenic mouse model. BBG was orally administered to APPSwDI/NOS2-/- mice for three months in order to assess its biocompatibility, its permeability across the blood-brain barrier, and its efficacy at rescuing AD pathology. The results showed that BBG was well-tolerated, caused no significant weight change/unusual behavior, and was able to significantly cross the AD blood-brain barrier in APPSwDI/NOS2-/- mice. Immunohistochemical and electron microscopic analysis of the brain sections revealed that BBG was able to significantly prevent neuronal loss and reduce intracellular APP/Aβ in hippocampal neurons. This is the first report of 1) the effect of Brilliant Blue G on neuronal loss in a transgenic animal model of AD, 2) oral administration of BBG to affect a protein conformation/aggregation disease, and 3) electron microscopic ultrastructural analysis of AD pathology in APPSwDI/NOS2-/- mice.
Export Options
About this article
Cite this article as:
Jacob A. Irwin, Alev Erisir, Inchan Kwon , Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160208142456
DOI https://dx.doi.org/10.2174/1567205013666160208142456 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Aluminum Excytotoxicity and NeuroAutotoImmunity: The Role of the Brain Expression of CD32+ (FcγRIIa), ICAM-1+ and CD3ع in Aging
Current Aging Science Crystallography of Membrane Proteins, Major Targets in Drug Design
Mini-Reviews in Medicinal Chemistry The Metabotropic Glutamate Receptor System: G-Protein Mediated Pathways that Modulate Neuronal and Vascular Cellular Injury
Current Medicinal Chemistry - Central Nervous System Agents Medicinal Chemistry of Indolylglyoxylamide TSPO High Affinity Ligands with Anxiolytic-Like Effects
Current Topics in Medicinal Chemistry Magnetic Resonance Elastography
Current Medical Imaging Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Cytokine Therapy for Cancer
Current Pharmaceutical Design Novel Anti-Inflammatory-Pro-Resolving Mediators and Their Receptors
Current Topics in Medicinal Chemistry Neural Plasticity After Spinal Cord Injury
Current Pharmaceutical Design Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Current Medicinal Chemistry Synthetic and Natural Coumarins as Antioxidants
Mini-Reviews in Medicinal Chemistry Ginsenoside RB1 Reduces Neurologic Damage, is Anti-Apoptotic, and Down-Regulates p53 and BAX in Subarachnoid Hemorrhage
Current Neurovascular Research <i>Lantana undulata</i> Schrank – A New Source of Biological Potential in the Verbenaceae Family
The Natural Products Journal Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Current Cancer Drug Targets Towards an Integrated Clinical Psychobiology of Alcoholism
Current Psychiatry Reviews Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Current Alzheimer Research